Alector Inc.(ALEC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALEC Alector Inc.

Post-Mkt 01-28 17:59:32 EST

1.91

-0.04

-2.05%

盘后1.91

+0.000.00%

16:10 EST

High1.97	Low1.85	Vol777.95K
Open1.96	D1 Closing1.95	Amplitude5.90%
Mkt Cap208.48M	Tradable Cap176.70M	Total Shares109.15M
T/O1.48M	T/O Rate0.84%	Tradable Shares92.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALEC","market":"US","secType":"STK","nameCN":"Alector Inc.","latestPrice":1.91,"timestamp":1769634000000,"preClose":1.95,"halted":0,"volume":777948,"hourTrading":{"tag":"盘后","latestPrice":1.91,"preClose":1.91,"latestTime":"16:10 EST","volume":1507,"amount":2878.37,"timestamp":1769634605134,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02051282051282053,"floatShares":92512099,"shares":109151472,"eps":-1.075386,"marketStatus":"Post-Mkt","change":-0.04,"latestTime":"01-28 17:59:32 EST","open":1.96,"high":1.965,"low":1.85,"amount":1480839.501,"amplitude":0.058974,"askPrice":2.17,"askSize":200,"bidPrice":1.51,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.075386,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769648400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1549515600000,"exchange":"NASDAQ","adjPreClose":1.95,"preHourTrading":{"tag":"盘前","latestPrice":1.9305,"preClose":1.95,"latestTime":"08:28 EST","volume":100,"amount":193.05,"timestamp":1769606920092,"change":-0.0195,"changeRate":-0.01,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.91,"preClose":1.91,"latestTime":"16:10 EST","volume":1507,"amount":2878.37,"timestamp":1769634605134,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.350154,"impliedVol":0.3646,"impliedVolPercentile":0.1594},"requestUrl":"/m/hq/s/ALEC/tweets","defaultTab":"tweets","newsList":[{"id":"2605145495","title":"There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2605145495","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605145495?lang=en_us&edition=fundamental","pubTime":"2026-01-22 18:45","pubTimestamp":1769078730,"startTime":"0","endTime":"0","summary":"The Alector, Inc. ( NASDAQ:ALEC ) share price has done very well over the last month, posting an excellent gain of 32...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alec/alector/news/theres-no-escaping-alector-incs-nasdaqalec-muted-revenues-de","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alec/alector/news/theres-no-escaping-alector-incs-nasdaqalec-muted-revenues-de","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","ALEC"],"gpt_icon":0},{"id":"2605848186","title":"Alector Ends Latozinemab Continuation Study: Reading the Signals for ALEC Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2605848186","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605848186?lang=en_us&edition=fundamental","pubTime":"2026-01-22 00:31","pubTimestamp":1769013107,"startTime":"0","endTime":"0","summary":"Alector ($ALEC) announced an update on their ongoing clinical study. Alector’s Latozinemab Continuation Study Ends: What Investors Should Know Stud...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alector-ends-latozinemab-continuation-study-reading-the-signals-for-alec-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alector-ends-latozinemab-continuation-study-reading-the-signals-for-alec-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ISBC","BK4139","ALEC"],"gpt_icon":0},{"id":"2605489377","title":"Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arrowhead Pharmaceuticals (ARWR) and Alector (ALEC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605489377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605489377?lang=en_us&edition=fundamental","pubTime":"2026-01-21 23:50","pubTimestamp":1769010619,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Belite Bio, Inc. ADR (BLTE – Research Report), Arrow...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-arrowhead-pharmaceuticals-arwr-and-alector-alec-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-arrowhead-pharmaceuticals-arwr-and-alector-alec-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4137","BK4588","BLTE","ALEC","BK4139","BK4581","XBI","XLV","BK4585","LU0029874061.USD","ARWR","LABU","HCSG","BK4007"],"gpt_icon":0},{"id":"2601844701","title":"Alector Unveils New Pipeline Advances and Brain Carrier Technology in Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601844701?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:01","pubTimestamp":1767747703,"startTime":"0","endTime":"0","summary":"Alector Inc. has released a new corporate presentation detailing updates on its leadership team, research programs, and proprietary technologies. The presentation highlights advancements in the Alector Brain Carrier  technology, designed to enable efficient delivery of antibodies, enzymes, and siRNA therapies across the blood-brain barrier. The company outlines its ongoing development of drug candidates targeting neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Gaucher Disease, and Lewy body dementia. The ABC platform is featured for its versatility, optimized transferrin receptor binding, and compatibility with multiple drug modalities. Financially, Alector reports a cash position sufficient to support operations through at least 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL5Kf54Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALEC"],"gpt_icon":0},{"id":"2591819816","title":"Alector Names Interim CFO Berkley to Role on Permanent Basis","url":"https://stock-news.laohu8.com/highlight/detail?id=2591819816","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591819816?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:24","pubTimestamp":1765574640,"startTime":"0","endTime":"0","summary":"Alector appointed Neil Berkley as chief financial officer on a permanent basis, effective Dec. 10.Berkley will also continue to be chief business officer, a role he's held since 2024, the biotechnology company said Friday.Berkley has held the company's top finance role on an interim basis since June. He succeeded Marc Grasso, who resigned from the position to take on the same role at Kyverna Therapeutics.Berkley has led corporate strategy, finance, business development and operations across early- and late-stage companies for more than two decades, the company said. He joined Alector in 2024.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALEC"],"gpt_icon":0},{"id":"2591681308","title":"Alector Names Neil Berkley as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2591681308","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591681308?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:16","pubTimestamp":1765574217,"startTime":"0","endTime":"0","summary":"Alector (ALEC) said late Friday it appointed Neil Berkley as chief financial officer, effective Dec. 10.Berkley, who had been serving as Alector's interim CFO since June, will also continue to serve as chief business officer, according to the company.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALEC","BK4139"],"gpt_icon":0},{"id":"2591568907","title":"Press Release: Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2591568907","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591568907?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:05","pubTimestamp":1765573500,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025  -- Alector, Inc. , a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer  since March 2024, and CBO and Interim Chief Financial Officer  since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO.Alector is a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as Alzheimer's disease, Parkinson's disease, and frontotemporal d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFO","ALEC","BK4139"],"gpt_icon":0},{"id":"2590536140","title":"Alector Inc. Principal Accounting Officer Grace Wong-Sarad Reports Common Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2590536140","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590536140?lang=en_us&edition=fundamental","pubTime":"2025-12-09 07:04","pubTimestamp":1765235051,"startTime":"0","endTime":"0","summary":"Grace Wong-Sarad, Principal Accounting Officer at Alector Inc., reported a disposal of common shares of Alector Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLnjmZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alector Inc. Principal Accounting Officer Grace Wong-Sarad Reports Common Stock Sale","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALEC"],"gpt_icon":0},{"id":"2588708085","title":"Alector to Participate in Bank of America CNS Therapeutics Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588708085","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588708085?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:05","pubTimestamp":1764623112,"startTime":"0","endTime":"0","summary":"Alector Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, will participate in a fireside chat at the Bank of America CNS Therapeutics Conference. The event will be held virtually on Monday, December 8, 2025, at 2:25 pm ET. A webcast of the session will be available on the Alector website, with a replay accessible for 90 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL3vnQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0001KFT4U8.USD","LU0208291251.USD","LU0306806265.USD","IE0034235188.USD","LU0321505439.SGD","LU1363072403.SGD","LU0787776722.HKD","LU1496350171.SGD","LU1791807156.HKD","LU1280957306.USD","IE00BKVL7J92.USD","LU0203347892.USD","BK4112","LU0203345920.USD","LU1035773651.USD","LU2210149790.SGD","LU2129689431.USD","LU1880398471.USD","LU1496350502.SGD","IE00B64PRP62.GBP","LU0683600562.USD","BK4559","BK4534","LU0648001328.SGD","LU0070302665.USD","IE0002270589.USD","IE00B19Z3581.USD","BAC","LU0477156953.USD","LU0106831901.USD","LU0310800965.SGD","BK4139","IE00BKPKM429.USD","IE00BBT3K403.USD","LU1804176565.USD","ALEC","LU0477156797.USD","LU1074936037.SGD","LU0130103400.USD","LU1267930227.SGD","BK4504","LU1894683264.USD","LU1883839398.USD","LU0130102774.USD","IE00B1BXHZ80.USD","BK4588","LU0128525689.USD","BK4553","NDAQ","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2584164647","title":"Alector Inc : Morgan Stanley  Cuts Target Price to $0.75 From $1.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2584164647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584164647?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:32","pubTimestamp":1763379136,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT0WV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALEC"],"gpt_icon":0},{"id":"2582313088","title":"Agilent and University of Melbourne Unveil Innovation Hub to Advance Environmental Research and Population Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2582313088","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582313088?lang=en_us&edition=fundamental","pubTime":"2025-11-12 07:00","pubTimestamp":1762902000,"startTime":"0","endTime":"0","summary":"Partnership underscores Agilent's expansion across Asia, including recent establishment of Centres of Excellence  within flagship university campuses in South Korea, Singapore and Malaysia MELBOURNE, Australia, Nov. 12, 2025 /PRNewswire/ -- Agilent Technologies Inc. announced the launch of its new Agilent Innovation Hub in partnership with the University of Melbourne, acting through the Australian Laboratory for Emerging Contaminants . The hub integrates Agilent's next-generation technologies, including an extensive portfolio of Infinity III Liquid Chromatography  systemsand ALEC's research expertise in the critical area of environmental health and safety. Bharat Bhardwaj, Vice President of APAC Sales at Agilent, and Assoc. Prof. Brad Clarke from the University of Melbourne, at the official unveiling of the Agilent Innovation Hub in Australia.\"This collaboration with Agilent shows what's possible when academia and industry work hand in hand. It allows us to move beyond measuring known ","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2819638/Agilent_and_University_of_Melbourne_Unveil_Innovation_Hub.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2819638/Agilent_and_University_of_Melbourne_Unveil_Innovation_Hub.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/agilent-and-university-of-melbourne-unveil-innovation-hub-to-advance-environmental-research-and-population-health-302611404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721428933.USD","LU2229751404.USD","ALEC","BK4585","IE00B19Z4B17.USD","HUBG","BK4139","BK4121","IE00BN0W2W23.USD","XAO.AU","IE00B7SZL793.SGD","XKO.AU","LU1543694498.USD","XJO.AU","LU2089279066.USD","LU2413666699.HKD","LU2092937221.SGD","LU1165135440.EUR","IE00B66KJ199.SGD","BK4567","LC","BK4166","LU2041044095.USD","IE00BN0W2V16.EUR","LU2413666426.HKD","BK4588","LU0347712357.USD","IE0031619046.USD","BK4131","IE00BN0W2T93.GBP","A"],"gpt_icon":0},{"id":"2582390889","title":"Mizuho Securities Keeps Their Hold Rating on Alector (ALEC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582390889","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582390889?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:17","pubTimestamp":1762895828,"startTime":"0","endTime":"0","summary":"In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Alector, with a price target of $1.50. According t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-hold-rating-on-alector-alec-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-hold-rating-on-alector-alec-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","ALEC"],"gpt_icon":0},{"id":"2582827907","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827907","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827907?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Barrick Mining Corp                                3Q       .60   6:00 AM. ·Belite Bio Inc. ADR                             3Q      (.49)      AMC. ·Blckstne Sec Ldg                                3Q       .78   6:50 AM. ·DHI Grp Inc.                                     3Q       .04   4:15 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d36bfa730d18775aec9ad51d0643309e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BKV","DDI","ASRT","BXSL","DHX","AIOT","APEI","AOMR","BTDR","AKBA","BAK","AMBC","TBPH","MNDY","BCSF","BODI","ACDC","ANTA","BEEP","ONTF","DCGO","DSP","BALY","CAMT","ALEC","DOX","AII","CNTY","BDTX","CART","BLTE","ARCT","BARK","CHGG","OSG","BEKE","ADCT","B","CGEN","AGEN","OXY","CAPR","AU","BW","DOLE","CEVA"],"gpt_icon":1},{"id":"2581049046","title":"Clinical biotech firm Alector Q3 revenue beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2581049046","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581049046?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:15","pubTimestamp":1762467350,"startTime":"0","endTime":"0","summary":"Clinical biotech firm Alector Q3 revenue beats expectationsOverviewAlector Q3 2025 revenue beats analyst expectations despite a year-over-year declineNet loss for Q3 2025 narrows compared to the same ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALEC","BK4139"],"gpt_icon":0},{"id":"2581045181","title":"Alector Unveils Pipeline Advances in Brain Disorder Treatments and Brain Carrier Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045181","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045181?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:48","pubTimestamp":1762465738,"startTime":"0","endTime":"0","summary":"Alector Inc. has provided updates on its latest development portfolio and proprietary brain delivery platform in a recent corporate presentation. The company highlighted progress in its Phase 2 clinical trial for Alzheimer's disease, with interim analysis expected in the first half of 2026. Alector is advancing several brain-penetrant therapeutic candidates, including anti-amyloid beta antibodies, GCase enzyme replacement therapy, and small interfering RNA  targeting tau, α-synuclein, and NLRP3. The presentation described the Alector Brain Carrier  platform, designed to facilitate efficient delivery of therapeutic molecules across the blood-brain barrier, with configurations adaptable for use with antibodies, enzymes, and nucleic acids. The company reported $291.1 million in cash, cash equivalents, and marketable securities as of November 6, 2025, providing a financial runway through 2027. You can access the full presentation through the link below.Disclaimer: This news brief was creat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLcbyqq1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALEC","BK4139"],"gpt_icon":0},{"id":"2581939043","title":"Alector Q3 EPS $(0.34) Beats $(0.42) Estimate, Sales $3.260M Beat $3.020M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581939043","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581939043?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:33","pubTimestamp":1762464827,"startTime":"0","endTime":"0","summary":"Alector Q3 EPS $(0.34) Beats $(0.42) Estimate, Sales $3.260M Beat $3.020M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48705069/alector-q3-eps-0-34-beats-0-42-estimate-sales-3-260m-beat-3-020m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alector Q3 EPS $(0.34) Beats $(0.42) Estimate, Sales $3.260M Beat $3.020M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALEC"],"gpt_icon":0},{"id":"2581017706","title":"Alector reports Q3 net loss of $34.7 million on $291.1 million cash position","url":"https://stock-news.laohu8.com/highlight/detail?id=2581017706","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581017706?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:08","pubTimestamp":1762463318,"startTime":"0","endTime":"0","summary":"Alector Inc. reported a net loss of $34.7 million, or $0.34 per share, for the quarter ended September 30, 2025, compared to a net loss of $42.2 million, or $0.43 per share, in the same period in 2024. General and administrative expenses for the quarter were $11.5 million, down from $15.8 million in the prior year period, primarily due to the absence of impairment charges and reduced personnel-related costs. As of September 30, 2025, cash, cash equivalents, and investments totaled $291.1 million, including $14.7 million raised through at-the-market equity offerings in September, and an additional $5.3 million raised in October. The company expects this cash position to fund operations through 2027. Guidance for 2025 includes collaboration revenue between $13.0 million and $18.0 million, research and development expenses between $130.0 million and $140.0 million, and general and administrative expenses between $55.0 million and $65.0 million. Key business developments include selection ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7KSC1p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","ALEC","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2581317010","title":"BRIEF-Alector Q3 Basic EPS USD -0.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2581317010","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581317010?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:05","pubTimestamp":1762463153,"startTime":"0","endTime":"0","summary":"BRIEF-Alector Q3 Basic EPS USD -0.34\n\n\nNov 06 (Reuters) - Alector Q3 revenue USD 3.26 million vs. IBES estimate USD 3.02 million.\n\nQ3 net income USD -34.667 million\nQ3 EPS USD -0.34","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX1A2324:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALEC","BK4139"],"gpt_icon":0},{"id":"2579346380","title":"Alector Inc  expected to post a loss of 41 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2579346380","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579346380?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:01","pubTimestamp":1761908468,"startTime":"0","endTime":"0","summary":"Alector Inc  expected to post a loss of41cents a share - Earnings Preview Alector Inc ALEC.OQ ALEC.O is expected to  show a fall in quarterly revenue when it reports  results on November 4 (estimated)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC0XS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALEC","BK4139"],"gpt_icon":0},{"id":"2577390297","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2577390297","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577390297?lang=en_us&edition=fundamental","pubTime":"2025-10-23 02:17","pubTimestamp":1761157074,"startTime":"0","endTime":"0","summary":"Alector  said Tuesday its phase 3 trial of latozinemab in frontotemporal dementia caused by a progranulin gene mutation failed to meet its primary clinical endpoint.Shares sank 47% following an increase in intraday trading volume to over 39.3 million from a daily average of about 1.3 million.Bgin Blockchain's  shares, priced at an initial public offering of 5 million shares at $6 each and debuted on Nasdaq on Tuesday, slumped by 16% on Wednesday, with an intraday trading volume of more than 698,000.Netflix's  shares sank 10% after it reported Q3 earnings late Tuesday of $5.87 per diluted share, up from $5.40 a year earlier but below the FactSet consensus analyst estimate of $6.96.More than 11.8 million shares traded intraday compared with a daily average of about 3 million.Price: 1.69, Change: -1.52, Percent Change: -47.35","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1674673691.USD","LU1778281490.HKD","NFLX","LU0256863811.USD","LU0127658192.USD","LU0868494617.USD","LU2237957811.SGD","BK4527","LU1720051108.HKD","LU2860962120.EUR","LU1720051017.SGD","LU0353189680.USD","LU1267930730.SGD","LU1988902786.USD","BK4532","LU0353189763.USD","LU2264538146.SGD","BK4588","LU1069344957.HKD","SGXZ81514606.USD","LU1435385759.SGD","LU2237957902.USD","BK4524","ALEC","LU2361044949.HKD","LU0210533765.USD","IE00BKVL7J92.USD","LU0077335932.USD","SGXZ23171101.USD","BK4598","SGXZ99366536.SGD","BGIN","LU2357305700.SGD","IE00BQXX3F31.USD","LU0203201768.USD","LU0786609619.USD","SGXZ51526630.SGD","LU0708995401.HKD","LU0882574139.USD","IE00BQXX3D17.EUR","LU2326559502.SGD","LU2361045086.USD","LU2552382215.SGD","BK4507","LU0097036916.USD","BK4566","IE00BQXX3C00.GBP","LU0234572021.USD","LU0672654240.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.alector.com","stockEarnings":[{"period":"1week","weight":0.0656},{"period":"1month","weight":0.3448},{"period":"3month","weight":0.2581},{"period":"6month","weight":0.3087},{"period":"1year","weight":0.1207},{"period":"ytd","weight":0.25}],"compareEarnings":[{"period":"1week","weight":0.0264},{"period":"1month","weight":0.0075},{"period":"3month","weight":0.0118},{"period":"6month","weight":0.1003},{"period":"1year","weight":0.1604},{"period":"ytd","weight":0.0199}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.047629},{"month":2,"riseRate":0.333333,"avgChangeRate":0.031253},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.117194},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.055292},{"month":5,"riseRate":0.428571,"avgChangeRate":0.030589},{"month":6,"riseRate":0.571429,"avgChangeRate":-0.004123},{"month":7,"riseRate":0.857143,"avgChangeRate":0.062831},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.001024},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.031305},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.094127},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.021962},{"month":12,"riseRate":0.571429,"avgChangeRate":0.077226}],"exchange":"NASDAQ","name":"Alector Inc.","nameEN":"Alector Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alector Inc.(ALEC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alector Inc.(ALEC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alector Inc.,ALEC,Alector Inc.股票,Alector Inc.股票老虎,Alector Inc.股票老虎国际,Alector Inc.行情,Alector Inc.股票行情,Alector Inc.股价,Alector Inc.股市,Alector Inc.股票价格,Alector Inc.股票交易,Alector Inc.股票购买,Alector Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alector Inc.(ALEC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alector Inc.(ALEC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction